Skip to main content

Adamas Appoints Anna Richo to Board of Directors

Written by Customer Service on . Posted in Public Companies.

EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Anna Richo, J.D., General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, Inc., to its Board of Directors. She will also serve on the Audit Committee. Ms. Richo brings over 30 years of leadership experience managing legal and compliance functions within the biotechnology and pharmaceutical industry, including UCB, Amgen, and Baxter Healthcare as well as prior public-company Board, Audit, and Finance Committee experience at Cytyc Corporation.
“We are delighted to welcome Anna to our board during this exciting time of growth for us as a commercial organization,” said David L. Mahoney, Chairman, Adamas. “Anna brings extensive and relevant operational expertise, and we look forward to her contributions as we continue to advance and evolve Adamas,” added Neil F. McFarlane, CEO.“I am excited to work with the Adamas Board of Directors and management team given the company’s strong patient focus,” said Ms. Richo. “I look forward to partnering with the team to help the company reach its long-term goals and deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society.”Having joined Cargill in 2019, Ms. Richo’s successful career path includes leadership roles in biotechnology and pharmaceutical companies as general counsel and leading compliance, intellectual property, and corporate litigation. Ms. Richo has previously been recognized as one of the ’Top 15 Women in Pharma’.  She holds a bachelor’s degree in industrial and labor relations from Cornell University and a J.D. degree from DePaul University, College of Law. She is a member of the Board of Trustees for DePaul University.About Adamas
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.Contact:

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.